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Cardiovascular diseases are now becoming the most
common cause of perioperative death due to either
cardiac-related death (heart failure, acute myocardial
infarction [MI], left ventricular failure) or stroke-related
death4, with pneumonia renal failure and sepsis being
the next most common4 (Fig. 2).
When both mortality and morbidity data are considered,
cardiac events occur in an estimated 1-5% of patients
undergoing non-cardiac surgery, and the cardiovascular
complication rate may reach 30% for patients undergoing
vascular surgery5,6. In recent years the introduction of
troponin assay for the diagnosis of perioperative MI7-14
led to an apparent further increase in the frequency of
perioperative MI from 1.4% with creatine kinase-MB
assay to 6.6%11. In a retrospective study15 performed on
869 patients who underwent major non-cardiac surgery,
troponin I elevations (> 0.4 g/l) were observed among
38% of patients with significant intraoperative events
such as hypotension, hypertension or unexpected blood
loss or readmitted to the intensive care unit for an acute
event on the ward. 
The overall frequency of MI in the whole surgical
population may appear low (< 1%), but the prevalence is
particularly concentrated among patients who undergo
major thoracic, abdominal or vascular surgery, especially
when they are ≥ 70 years16-18, and among patients with
underlying coronary artery disease (CAD). In particular,
the risk of perioperative MI or cardiac death is < 1% for
patients who do not have CAD19, but increases twice in
the presence of known or suspected coronary or
atherosclerotic vascular disease19-25. A further 3 to 5-fold
increase was reported in patients selected to undergo
The dimension of the problem
Between April 1998 and March 1999 the National
Confidential Enquiry into Patient Outcome and Death,
collected a total of 32 956 in-hospital deaths within 30
days of an operative procedure (24 920 after emergency
surgery and 8036 after non-emergency surgery1). Total
procedures were 2.3 million (644 463 emergency surgery
and 1.7 million non-emergency surgery) resulting in an
approximate mortality rate of 1.4% (3.9% after
emergency surgery or 0.5% after non-emergency
surgery)1. Almost half of deaths occurred within the first
5 days with a distribution of the number of calendar
days between operation (day 0) and death which has
remained remarkably unchanged over the years2 (Fig. 1).
Patient disease is recognised as the most relevant of the
three components of perioperative risk of death
(anaesthesia, surgery and patient disease). More
precisely, in a survey considering over 1 million cases of
anaesthesia in a 1-year period (1987, about 485 850
operations), perioperative mortality was due to
intercurrent disease in 44% of overall mortality, although
the main cause was represented by the patient
presenting disease (67% of overall mortality)3.
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Advances in surgical and anaesthetic techniques and an aging
patient population have resulted in more complex procedures
being performed in greater numbers of aged subjects and in
patients with a high likelihood of significant cardiovascular
disease. Nearly one fourth of non-cardiac surgical procedures
(major intra-abdominal, thoracic, vascular, and orthopaedic
procedures) performed in persons older than 65 years have
been found to be associated with significant perioperative
cardiovascular morbidity and mortality. 
During previous years the main attempt was to define strategies
to accurately estimate perioperative cardiovascular risk based
either on the characteristics of surgery and on patient
characteristics. More recently preventive medical strategies
have been proposed. Therefore, the physician has to be aware of
the key elements useful to calculate the perioperative
cardiovascular risk, and of the medical preventive treatment or
further interventions to adopt in patients candidate to surgery.
(Intern Emerg Med 2006; 1 (3): 177-186)
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preoperative thallium scintigraphy26-31. In addition, the
prevalence of cardiovascular disease increases with age
and nearly one fourth of non-cardiac surgical procedures
(major intra-abdominal, thoracic, vascular, and
orthopaedic procedures) performed in subjects > 65 years
have been associated with significant perioperative
cardiovascular morbidity and mortality32. Therefore, in
the preoperative evaluation, special attention should be
placed to identify patients at risk of myocardial
ischaemia32.
Almost half of the patients who experience cardiac
morbidity develop other types of non-cardiac
complications and mortality33. To control healthcare
costs, hospital stays have been shortening in western
countries to bring hospital expenditure in line with
diagnosis-related group reimbursement. Likewise,
ambulatory surgery or same day admission for major
surgery are now widely used with the introduction of
critical pathways and the development of protocols
reducing the use of routine laboratory diagnostic tests for
preoperative evaluation34. This aspect is critical because
failure in preoperative evaluation or immediately
perioperative care may result in increased costs. One
million people having perioperative cardiac
complications over the 27 million men and women
having surgery each year in the United States, require
approximately 20 billion in costs of in-hospital and long-
term care35. 
To better understand the key elements useful to calculate
the perioperative cardiovascular risk in patients referred
to the surgeon it is important to know the
pathophysiological mechanisms responsible for
perioperative MI. 
Pathophysiology of perioperative myocardial
infarction
Perioperative MI mainly occurs either at the end of the
surgical procedure or 24-96 h after non-cardiac surgery36-38.
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Figure 1. Distribution of the number of calendar days between operation (day 0) and death.
Figure 2. Final primary diagnosis of perioperative death (n = 310 274) collected by the National Confidential Enquiry into Patient Outcome and
Death between 1 April  2003 and 31 March 2004.
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Although the mechanism underlying perioperative MI is
unknown, it was assumed to resemble that of non-
surgical MI39, that is, acute plaque rupture and coronary
thrombosis40,41. This hypothesis mainly stem on the large
prevalence of ulcerated plaques and coronary thrombosis
(> 45%) found in retrospective studies performed on
autopsy records of patients who underwent elective or
emergency non-cardiac surgery and fatal perioperative
MI between 1980 and 199039,42. However, in high-risk
patients undergoing vascular surgery under
electrocardiographic monitoring7, the majority of
ischaemic events (67%) including those culminating in
MI, were reported to start between 50 min before and 60
min after the end of surgery and during the emergence
from anaesthesia, a time characterised by an increase in
heart rate, blood pressure, and sympathetic discharge43.
In 67% patients with perioperative MI, the troponin
levels reached values above the 99th percentile of the
reference population (diagnosis of MI) within < 18 h after
the end of surgery with no ST-segment elevation or Q-
wave MI7. In addition, coronary angiography performed
in a small subgroup of patients with perioperative MI
within 7 days of MI revealed the presence of chronic
severe CAD without thrombus or ulcerated plaques7.
These findings support the hypothesis that
haemodynamic changes may play a prevalent role at the
end of surgery and in the early postoperative hours. A
significant decrease in coronary and myocardial blood
flow may indeed occur as a consequence of tachycardia
in the presence of fixed, but severe, coronary artery
stenosis, due to shortening of the diastolic time
period44,45. Vasoconstriction secondary to ischaemia may
further decrease coronary blood flow46,47. The hypothesis
that prolonged tachycardia and stress-induced ischaemia
underlie the evolution of perioperative MI is furtherly
supported by the reduction in cardiac death rates from 34
to 3.4% by prophylactic preoperative bisoprolol
treatment in high-risk patients undergoing major
vascular surgery48. Therefore, the pathophysiology of
early perioperative MI seems to be related to a prolonged
imbalance between myocardial oxygen supply and
demand in the setting of CAD. 
The onset of postoperative inflammatory reaction seems
to play a role in the occurrence of MI in the following
postoperative days. In particular, the inflammatory
activation may be responsible for fluid shifts16,23,49, for
the creation of a hypercoagulable environment, and for
functional alterations in distant organs. Major surgery
and, in particular, abdominal aortic surgery are followed
by extensive changes in the plasma levels of coagulation
factors and in thromboelastographic parameters leading
to a hypercoagulable state. An early impairment of
fibrinolysis with higher amounts of plasminogen
activator inhibitor-1 was observed in the early
postoperative period (24 h) after infra-inguinal
reconstruction50 and in patients undergoing lower-
extremity vascular reconstruction51 and remained
elevated through the second day. A return to baseline
values of plasminogen activator inhibitor-1 and
fibrinolysis was observed at day 3. Marked decreases in
the naturally occurring anticoagulants, protein C and
antithrombin III, and in alpha2-macroglobulin were also
reported in the following days (days 2-4)52. When
patients undergoing abdominal aortic surgery, carotid
endarterectomy and femoro-popliteal bypass were
compared, an increase in plasma fibrinogen and factor
VIII coagulant activity was observed in all the three
procedures. Conversely, there was a decrease in
antithrombin and protein C, and an increase in thrombin-
antithrombin complex levels in the abdominal aortic
group only53. This temporary increase of the tissue
plasminogen activator inhibitor may be responsible for
an impairment of fibrinolysis and an increase in the risk
of myocardial ischaemia54. 
After major non-cardiac surgery, in particular major
abdominal surgery55, cancer surgery56, and vascular
surgery57, an early increase in plasma concentrations of
both pro- and anti-inflammatory cytokines was also
reported. A close relationship between cytokine release
and the extension of surgical trauma58-60, and in
particular with the extension of ischaemia and
reperfusion61, was observed in aortic aneurysm surgery.
Recent findings indicate that proinflammatory cytokines
affect vascular function and endothelium-derived factors
involved in blood pressure regulation. Tumour necrosis
factor-alpha and interleukin-6 were both shown to
induce structural as well as functional alterations in
endothelial cells62. These cytokines enhance the
formation of a number of endothelial cell substances,
such as endothelin; reduce acetylcholine-induced
vasodilatation; and destabilise the mRNA of endothelial
nitric oxide synthase62,63. Thus, proinflammatory
cytokines may contribute to cause endothelial
dysfunction in postoperative days. 
Attempts have been made to define the systemic
inflammatory reaction on the basis of simple clinical
criteria, but their clinical meaning in the postoperative
period remains to be established. During the early days
in intensive care unit after surgery, the percentage of
patients with positive criteria for a systemic
inflammatory response (temperature > 38°C,
leucocytosis, tachypnoea, and tachycardia) is much
higher (93%) than mortality (8.2%) of the same group64,
so that the prognostic value of systemic inflammatory
response syndrome (SIRS) was questioned. Indeed, part
of these criteria may be related to sympathetic activation
(postoperative pain) rather than to inflammation.
However, when SIRS criteria persists for 2 consecutive
days after postoperative day 3, the negative prognostic
value is high61,66. 
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pulmonary function is also often described as a
significant predictor of perioperative mortality71-75.
Combination of different perioperative strategies
designed to emphasise respiratory therapy in high-risk
patients may reduce the risk of pulmonary78 and
subsequent cardiac33 complications. 
A simple esteem of the functional capacity of the patient
can be obtained during the history32 (Table 1). Poor
functional capacity in patients with CAD is associated
with increased incidence of subsequent cardiac events
and exercise test was one of the first non-invasive
technologies used in preoperative cardiac risk
stratification. In most ambulatory patients the test of
choice is exercise electrocardiographic testing. The
positive predictive value of postoperative death or MI of
abnormal results of an exercise test ranges from 5 to 25%
with a negative predictive value of normal results of a
maximal test exceeding 90%32. In patients unable to
perform adequate exercise (30-50% of cases)79, a non-
exercise stress (dipyridamole myocardial perfusion
imaging testing and dobutamine echocardiography test)
has to be considered. The expertise of the local
laboratories is often more important than the particular
type of test32 (Table 2).
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Preoperative evaluation and clinical prediction
To reduce the incidence of perioperative cardiovascular
complications and to minimise the costs of redundant
perioperative tests, the American College of Cardiology
(ACC), the American Heart Association (AHA) and the
American College of Physicians produced practice
guidelines for perioperative evaluation in non-cardiac
procedures32. Two main factors contribute to
perioperative risk, the first related to the type of surgery
and degree of haemodynamic cardiac stress associated
with surgery-specific techniques, the second related to
patient characteristics32. In some cases, such as in
vascular surgery for peripheral vascular disease, the two
conditions coexists due to frequent co-morbidities (CAD,
congestive heart failure, cerebrovascular disease, and
renal and pulmonary disease)67-76. 
Considerable risk is also present when surgery is
performed as an emergency procedure especially in the
elderly. However, a first relevant consideration is that
preoperative cardiac evaluation has to be adapted to the
circumstances that have required consultation and the
nature of the illness. Therefore, at variance with elective
surgical procedures, both in acute emergency and when
good care requires prompt surgery (bleeding cancer),
only limited essential critical tests (vital signs, volume
status, renal function) are required and it is often not
necessary to perform additional tests, especially when
coronary revascularisation is not an option. 
Perioperative evaluation for elective surgery often
represents the first careful cardiovascular evaluation for
the patients over the years. The visit should therefore be
considered as an ideal opportunity to affect long-term
treatment of a patient with cardiac disease or at risk of
such disease and the referring physician should be
informed of the results of the evaluation. History should
be especially addressed to investigate serious cardiac
conditions (prior angina, recent or past MI, heart failure,
symptomatic arrhythmias, pacemaker, implantable
cardioverter-defibrillator), co-morbid diseases (peripheral
vascular disease, cerebrovascular disease, diabetes
mellitus, renal impairment, peripheral vascular disease,
cerebrovascular disease, renal failure) and risk factors.
Diabetes, hypertension, angina or heart failure may often
be diagnosed for the first time at preoperative
consultation. It is well recognised that undiagnosed
diabetes in the US population aged 20-74 years was 2.0
and 2.4% in the years 1976-1980 and 1999-2000,
respectively, with a prevalence of 3.3 and 5.8% of
diagnosed diabetes77. Risk factors, such as hypertension
and chronic pulmonary disease, seem to play a role as
predictors of outcome71-75. Patients with poorly
controlled hypertension or labile preoperative
hypertension have an increased risk for perioperative
dysrhythmias and myocardial ischaemia32. Poor
Table 1. Estimated energy requirements for various activities.
1-4 METS
Can you take care of yourself? 
Eat, dress, or use the toilet?
Walk indoors around the house?
Walk a block or two on level ground at 2-3 mph or 3.2-4.8 km/h?
Do light work around the house like dusting or washing dishes?
4-10 METS
Climb a flight of stairs or walk up a hill?
Walk on level ground at 4 mph or 6.4 km/h?
Run a short distance?
Do heavy work around the house like scrubbing floors or lifting or
moving heavy furniture?
Participate in moderate recreational activities like golf, bowling, dancing,
doubles tennis, or throwing a baseball or football?
> 10 METS
Participate in strenuous sports like swimming, singles tennis, football,
basketball, or skiing?
Table 2. Predictive value of three preoperative stress tests.
Predictive value (%) No. studies
Positive Negative
Exercise
ECG stress test 5-25 90-100 10
Non-exercise*
Myocardial perfusion imaging 4-27 95-100 27
Dobutamine stress echo 7-33 93-100 11
* patients who cannot exercise, left bundle branch block, preexcitation (Wolff- 
Parkinson-White), pacemaker, ST-segment depression at rest > 1 mm.
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In patients with CAD three aspects should be clarified: 1)
the amount of damaged myocardium, 2) the ischaemic
threshold, and 3) the ventricular function. Clarification of
these three questions represents an important goal of
preoperative evaluation and supplemental testing may
sometimes be required. The decision to require a test
represents a balance between the possibility of
identifying advanced or non-suspected CAD, which
might result in significant cardiac morbidity or mortality
either perioperatively or in the long term, and the risks
from the test and treatment in itself which may offset and
even exceed the potential benefit of evaluation.
Perioperative therapy, and in particular beta-blockade,
represents an excellent strategy in patients at increased
risk for perioperative mortality, especially when coronary
revascularisation for long-term benefits is not a serious
consideration. 
Perioperative interventions
On the basis of two studies5,80, the ACC/AHA task force
on guidelines for non-cardiac surgery recommended
perioperative beta-blockers for patients with
preoperative stress test ischaemia having vascular
surgery (class I recommendation) and for patients with
established CAD, risk factors for CAD, or untreated
hypertension having non-cardiac surgery (class IIa
recommendation)32. In these two major studies,
preoperative administration of beta-blockers titrated to a
dose to achieve a resting heart rate of 50-60 bpm showed
favourable effects on perioperative MI in high-risk
patients undergoing major vascular surgery5,80. 
In the first study the administration of atenolol (5-10 mg
i.v. 30 min before and after surgery followed by 50-100
mg/day up to 7 days) to patients at risk of CAD
(previous MI, typical angina, positive stress test, age > 65
years, hypertension, current smoking, plasma cholesterol
> 240 mg/dl, diabetes mellitus) significantly reduced
both the primary endpoint (death in patients who
survived to hospital discharge) and the combined
endpoint (MI, unstable angina, need for coronary artery
bypass grafting, congestive heart failure) at 6 months, 1
and 2 years after operation80. The study by Mangano et
al.80 was criticised because in-hospital deaths and
adverse events were ignored in the analysis, patients who
were already on beta-blockers had them discontinued on
entry and results of “intention-to-treat” analysis were not
given81. When the six deaths that occurred during the
period when patients received the study drug are
appropriately included in the intention-to-treat analysis,
the reduction in the risk of death with atenolol is no
longer significant. 
The second study evaluated the effect on 1-month
mortality in patients with positive dobutamine stress echo
who were not already on beta-blockers5. In particular, any
patient with a risk factor (age > 70 years; angina; prior MI
on the basis of history or a finding of pathologic Q waves
on electrocardiography; compensated congestive heart
failure or a history of congestive heart failure; current
treatment for ventricular arrhythmias; current treatment
for diabetes mellitus; or limited exercise capacity, defined
as the inability to perform most normal daily activities)
underwent dobutamine echocardiography. Patients with
a positive result at dobutamine test were considered at
high risk. Patients were excluded if they had extensive
wall motion abnormalities (wall motion index > 1.70 at
rest), asthma, or strong evidence during stress testing of
left main or three-vessel CAD. Bisoprolol, a selective
beta1-adrenergic receptor antagonist, was started (5
mg/day orally) at least 1 week before surgery and the
dose was increased after 1 week (10 mg/day) if heart rate
remained > 60 bpm. The same dose of bisoprolol was then
continued postoperatively (30 days) except in patients
who were unable to take medication orally or by
nasogastric tube postoperatively. These patients received
intravenous metoprolol to keep the heart rate < 80 bpm.
Bisoprolol was withheld if the heart rate was < 50 bpm or
the systolic blood pressure was < 100 mmHg immediately
before each scheduled dose. The interim analysis of the
Poldermans study demonstrated a 100% risk reduction in
non-fatal MI (diagnosed at electrocardiography and by
assay of serum creatine kinase level with the MB fraction)
and a 80% risk reduction in cardiovascular death during
the perioperative period (30 days); therefore the trial was
stopped early.
The inclusion of these two studies in a recent meta-
analysis considering randomised controlled trials
published from 1996-2004 evaluating perioperative beta-
blockers in non-cardiac surgery (6 studies for a total of
632 patients)82 led to favourable conclusions showing a
decrease in long-term cardiac mortality from 12 to 2%
and a decrease in myocardial ischaemia from 33 to 15%.
All outcomes except perioperative overall mortality had
improvements (p < 0.02), with a number needed to treat
of 20, 11, 10, 14 and 9 for perioperative cardiac mortality,
long-term overall mortality, long-term cardiac mortality,
MI and myocardial ischaemia, respectively82. Those
conclusions were challenged by a contemporary meta-
analysis81 which questioned the robustness of the
evidence included by McGory et al.82. The study
considered 22 randomised controlled trials with a total of
2437 patients, but for predefined quality reasons
excluded from calculations both the two studies
considered by the ACC/AHA task force guidelines5,80.
On the basis of included studies, perioperative beta-
blockers showed only a statistically significant beneficial
relative risk reduction (0.44; 95% confidence interval [CI]
0.20-0.97, 99% CI 0.16-1.24, p < 0.04) for the composite
outcome of cardiovascular mortality, non-fatal MI, and
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non-fatal cardiac arrest with no statistically significant
beneficial effects on any of the individual outcomes81.
The individual safety outcomes in patients treated with
perioperative beta-blockers showed a relative risk for
bradycardia needing treatment of 2.27 (95% CI 1.53-3.36,
99% CI 1.36-3.80) and a nominally statistically significant
relative risk for hypotension needing treatment of 1.27
(95% CI 1.04-1.56, 99% CI 0.97-1.66). However, the meta-
analysis by Devereux et al.81 included also studies
performed either on low-risk patients, or on low-risk
surgery, two conditions not strictly considered in the
ACC/AHA recommendations for the perioperative use
of beta-blockers. 
A new large trial is now ongoing, the Perioperative
Ischaemic Evaluation (POISE) trial, which plans to recruit
10 000 patients, and has already recruited more than 4000
patients in 18 countries. While awaiting clear evidence
from the results of the POISE study, the use of beta-
blockers can be considered for patients with positive
preoperative stress test ischaemia having vascular
surgery (class I recommendation) and for high-risk
patients having non-cardiac surgery32. 
The group of patients at high risk for clinical risk factors
and non-invasive testing often has considerable
perioperative mortality despite beta-blocker use72. For
these patients undergoing non-cardiac procedures
including major vascular surgery, a combination of beta-
blockers with statins may offer additional prevention83-85.
In patients in whom, despite the combination of beta-
blockers and statins, the estimated probability remains
high and there is clear indication for coronary
revascularisation independent of the need for vascular
surgery, a coronary intervention should be considered32.
After surgery, cardiovascular secondary prevention has
to be especially considered when postoperative troponin
elevation is detected. 
Which prognostic role for perioperative troponin
rise?
In the vast majority of postoperative patients the
elevations of cardiac-specific markers is caused by
thrombotic obstruction and/or impaired myocardial
perfusion in the context of an acute coronary syndrome86.
However, several studies have also raised the question of
the unexpectedly high percentage of elevated troponin
levels in surgical intensive care unit patients without
underlying coronary syndromes87,88. 
The release of cardiac troponin can be due to irreversible
or reversible cell damage89. In prolonged ischaemia, the
increase in troponin I is related with irreversible damage
of cardiomyocytes90 but patients with unstable angina
have only transient troponin elevations, with values
returning to baseline within a few hours91. In a study by
Suleiman et al.92, short periods (3 min) of regional
ischaemia and reperfusion resulted in the release of
significant amounts of troponin. Moreover, animal
studies and other indirect clinical evidence have also
suggested that troponin can be released in reversible
ischaemia93. Therefore the ACC/AHA guidelines do
indicate that MI should be diagnosed in conjunction with
other supportive evidence14. 
In the setting of postoperative inflammatory states
(SIRS/sepsis), the release of myocardial depressant
substances, such as tumour necrosis factor, might cause
degradation of free troponin in situ to lower-molecular-
weight fragments94. With increased membrane
permeability, those smaller troponin fragments could be
released into the systemic circulation. In this setting,
myocyte damage may not be permanent, and thus cell
necrosis does not occur95. A high incidence of abnormal
troponin I was found in septic patients (17/20, 85%)
independently of CAD as demonstrated by coronary
angiography, stress echocardiography or histologic
findings on the available autopsies95. Likewise, ver Elst et
al.96, in half of the autopsy cases with a positive pre-
mortem troponin I, did not demonstrate irreversible
myocyte necrosis (e.g. contraction band necrosis)96. The
assessment of whether troponin elevation is expression
of myocardial ischaemia or is caused by reversible non-
ischaemic myocardial injury can be, therefore,
challenging. Ischaemic electrocardiographic changes,
chest pain, wall motion abnormalities on
echocardiography, irreversible deficit on radionuclide
imaging (thallium) and the presence of atherosclerotic
risk factors may be associated with a thrombotic origin of
troponin elevation97. On the other hand, in patients with
a low pre-test probability of CAD the main goal is to
identify the underlying cause of troponin elevation,
which frequently becomes evident during a
perioperative period (such as myocarditis, pericarditis,
sepsis, pulmonary embolism)89. Troponins maintain their
diagnostic and prognostic value also in patients with
chronic renal failure, being predictive not only of
cardiovascular mortality but also of general mortality in
this patient group98,99.
The possibility of performing strategies of myocardial
reperfusion in perioperative MI is limited because of the
high risk of bleeding. Therefore, the issue of
cardiovascular risk in these patients with isolated
(without other clinical signs of myocardial ischaemia)
troponin increase at medium and long-term follow-up
becomes relevant.  In a prospective study performed in
229 patients undergoing aortic or infrainguinal vascular
surgery100, at 6-month follow-up an abnormal troponin
serum level (> 1.5 ng/ml) in the perioperative period was
associated with a 6-fold increased risk of mortality
(adjusted odds ratio [OR] 5.9; 95% CI 1.6-22.4) and a 27-
fold increased risk of MI (OR 27.1; 95% CI 5.2-142.7). At
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1-year follow-up, about 16% of patients with CAD or at
high risk of CAD undergoing major non-cardiac surgery
(n = 173) died101. Elevation of troponin I (> 2 g/l on the
first and/or second postoperative mornings) was
strongly associated with the 12-month all-cause mortality
(OR 6.5, 95% CI 2.6-16). During a 1 to 5-year follow-up
period (mean 32.3 ± 13.8 months), 82 out of 447
consecutive patients who underwent major vascular
surgery patients died (18.3%)102. Increased troponin
measured immediately after surgery and every morning
in the first 3 postoperative days, was found an
independent predictor of long-term mortality at both low
(troponin I > 0.6 ng/ml and/or troponin T > 0.03 ng/ml)
and high cut-off levels (troponin I > 3.1 ng/ml and/or
troponin T > 0.2 ng/ml) (OR 2.30, 95% CI 1.49-3.55, and
3.41, 95% CI 1.81-6.43, respectively)102. 
These data indicate that an  isolated troponin increase in
patients without clinical evidence for ischaemia should
not be dismissed as false positive results and that these
patients may warrant further cardiac evaluation. 
Conclusions
The identification of patients at the highest risk of
perioperative MI is one of the main goals of preoperative
evaluation. In the clinical course of the surgical patient, a
first phase characterised by an increased sympathetic
discharge, corresponding to the end of surgery and
emergence from anaesthesia, is followed by a second
phase in which different factors contribute to create a
hypercoagulable and proinflammatory environment
(SIRS). Perioperative myocardial ischaemia may occur in
both phases with different mechanisms requiring
different prevention strategies. The early identification
and management of subclinical myocardial injury is
particularly relevant to start secondary prevention early
in order to avoid the progression to myocardial failure.
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